Biotech participation is widening. An industry rank near the top of screens, heavier dollar volume, and a high share of rising constituents point to risk appetite returning beyond a few mega-cap leaders. That can keep the group in rotation, but durability will hinge on July and August clinical and FDA catalysts.
Breadth and volume have improved together. Recent market data show an industry rank score near 95, with roughly 13% one-month gains and around 36% three-month gains. Relative dollar volume is running near 2.2 times its recent five-day norm and about 1.6 times the 20-day pace. Roughly 84% of index constituents are positive over three months, more consistent with early-stage expansion than a one-name melt-up.
Platforms reassert leadership
Moderna, Inc. (
$MRNA
Moderna, Inc.
$67.27
) is a useful bellwether for platforms. Recent figures show shares up about 43% over one month and trading near 52-week highs. The next quarterly update later this summer will matter for how the market prices a multiyear platform rather than a single franchise. Watch gross margin direction and cash use as respiratory and latent-virus programs develop.
Diagnostics and tools pick up
10x Genomics, Inc. (
$TXG
10x Genomics, Inc.
$36.75
) and Twist Bioscience Corporation (
$TWST
Twist Bioscience Corporation
$99.84
) are riding the research pickup.
$TXG
10x Genomics, Inc.
$36.75
rose about 49% over one month and recently set a 52-week high. The company said on June 9 that it acquired Proteintech Genomics, expanding proteomics capabilities to support a multiomic roadmap across its single-cell and spatial platforms, including the planned protein layer for the Atera platform.
$TWST
Twist Bioscience Corporation
$99.84
gained roughly 54% over one month and also printed a 52-week high. May commentary from the company highlighted expanded clonal-gene offerings to include longer and more complex sequences, a nod to rising demand as AI-guided protein design and nucleic-acid therapeutics work scales up. Order confirmation remains the swing factor, a point made in Lab Tools Break Out, Now Orders Must Confirm.
Specialty pharma momentum
Alkermes plc (
$ALKS
Alkermes plc
$55.08
) has quietly joined the leaders, rising around 48% over one month and making new highs. The upcoming earnings window will test whether product revenue and margin mix can support that move and whether operating discipline can sustain double-digit growth at this stage of the cycle.
A diagnostics pivot to watch
Adaptive Biotechnologies Corporation (
$ADPT
Adaptive Biotechnologies Corporation
$20.96
) said in mid-June that it plans to separate its Minimal Residual Disease diagnostics and Immune Medicine businesses, with a preferred path to separation expected by year-end 2026. Management disclosed that MRD has reached profitability, anchored by clonoSEQ, while Immune Medicine may pursue capital outside the current structure. Shares are up roughly 48% over one month, but the separation path and timing remain subject to review and market conditions.
A binary FDA test for sentiment
Replimune Group, Inc. (
$REPL
Replimune Group, Inc.
$11.63
) faces an early-August FDA target action date for RP1 in melanoma after prior treatment with programmed cell death protein 1 immune checkpoint inhibitors, with an advisory committee expected in late July. Shares climbed about 153% over one month, underscoring how quickly sentiment can swing ahead of binary events. The outcome may read across to other oncology filings after recent leadership changes at the agency, but it also highlights the execution and study-design scrutiny that can swing decisions.
Where the case can break
Small and mid-cap biotechs still live and die by single trials and cash runways. A handful of approvals or complete response letters in July and August could flip sentiment fast. For tools and platforms, order linearity and capital budgets at research customers can cool momentum if lab spending pauses. The same “orders are the test” dynamic shows up in PDF Solutions at Highs, Orders Are the Test.
July catalysts will test the breadth
The July calendar brings several advisory meetings and Prescription Drug User Fee Act target dates, plus earnings for tools and specialty pharma. For platforms, watch revenue cadence and cash use at
$MRNA
Moderna, Inc.
$67.27
. For tools, track 10x integration progress and whether single-cell and spatial demand broadens in the back half. For
$TWST
Twist Bioscience Corporation
$99.84
, order growth durability and pricing power into fiscal updates will matter. For diagnostics, watch Adaptive’s separation milestones and MRD uptake. Across the group, monitor follow-on financing behavior if the tape softens, which would indicate how durable this breadth expansion really is.
